N/A
N=88
Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant
Postoperative Nausea and Vomiting
Bottom Line
View on ClinicalTrials.gov: NCT02597907 ↗Enrolled (actual)
88
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: The Incidence of Postoperative Nausea and Vomiting — 5; 18 Participants — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- aprepitant (Drug); palonosetron (Drug); Ramosetron (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Kyungpook National University Hospital
- Primary completion
- May 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Incidence of Postoperative Nausea and Vomiting |
5; 18 | <0.05 sig |
Summary
The purpose of this study was to compare the antiemetic efficacy of aprepitant plus palonosetron versus aprepitant plus ramosetron in high risk patients undergoing laparoscopic cholecystectomy.
Eligibility Criteria
Inclusion Criteria
- Non smoking, female patients, scheduled for laparoscopic cholecystectomy
Exclusion Criteria
- Patients with gastrointestinal disorder,
- Patients with allergies to any study medication,
- Patients who had received any sedatives, opioid, steroid or antiemetics within 24 h before surgery
Data sourced from ClinicalTrials.gov (NCT02597907). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.